Skip to main content

Table 3 Adverse events

From: Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

AE All grade 3/4 1 2 3 4
Anemia 21(25.00%) 4(4.76%) 7(8.33%) 10(11.90%) 4(4.76%) 0
Neutropenia 63(75.00%) 38(45.24%) 7(8.33%) 18(21.43%) 21(25.00%) 17(20.24%)
Thrombocytopenia 17(20.24%) 7(8.33%) 1(1.19%) 9(10.71%) 6(7.14%) 1(1.19%)
Neuropathy 42(50.00%) 6(7.14%) 27(32.14%) 9(10.71%) 6(7.14%) 0
Diarrhea 2(2.38%) 0 1(1.19%) 1(1.19%) 0 0
Anorexia 3(3.57%) 0 3(3.57%) 0 0 0
Fatigue 14(16.67%) 0 9(10.71%) 5(5.95%) 0 0
Rash 28(33.33%) 2(2.38%) 15(17.86%) 11(13.09%) 2(2.38%) 0
Blurred vision 8(9.53%) 0 7(8.33%) 1(1.19%) 0 0
Dry eye 1(1.19%) 0 1(1.19%) 0 0 0
Eye pain 1(1.19%) 0 1(1.19%) 0 0 0
Alopecia 34(40.48%) 0 6(7.14%) 28(33.33%) 0 0
Nausea and vomiting 21(25.00%) 0 17(20.24%) 4(4.76%) 0 0
Nail change 19(22.62%) 0 15(17.86%) 4(4.76%) 0 0
Mucositis 6(7.14%) 0 2(2.38%) 3(3.57%) 1(1.19%) 0
Edema 20(23.80%) 0 14(16.67%) 6(7.14%) 0 0
Liver enzyme escalation 6(7.14%) 0 3(3.57%) 3(3.57%) 0 0
Hematuria 2(2.38%) 0 2(2.38%) 0 0 0
Skin hyperpigmentation 8(9.53%) 0 8(9.53%) 0 0 0
Hyperhidrosis 1(1.19%) 1(1.19%) 0 0 1(1.19%) 0
Febrile neutropenia 2(2.38%) 2(2.38%) 0 0 1(1.19%) 1(1.19%)
Myalgia 20(23.81%) 0 17(20.24%) 2(2.38%) 1(1.19%) 0
Hypersensitivity 1(1.19%) 1(1.19%) 0 0 1(1.19%) 0
Epistaxis 2(2.38%) 0 2(2.38%) 0 0 0
Abdominal distension 3(3.57%) 0 2(2.38%) 1(1.19%) 0 0
Pneumonitis 1(1.19%) 0 0 1(1.19%) 0 0